SCHEMBL4807382

SCHEMBL4807382

C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(OC(=O)CCO)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.59
MAPT P10636 3/20 0.59
CYP19A1 P11511 9/20 0.52
CYP3A4 P08684 2/20 0.50
MEN1 O00255 2/20 0.48
NR3C1 P04150 2/20 0.48
PGR P06401 2/20 0.48
KMT2A Q03164 2/20 0.48
HIF1A Q16665 2/20 0.48
HPGD P15428 1/20 0.48
MLNR O43193 1/20 0.48
NR1I2 O75469 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
HTT P42858 1/20 0.48
SLC6A3 Q01959 1/20 0.48
PDE4D Q08499 1/20 0.48
PDE3A Q14432 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
AR P10275 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439469 0.87 LMNA (0.59) LMNAMAPTCYP19A1CYP3A4MEN1
SCHEMBL11806510 0.85 LMNA (0.57) LMNAMAPTCYP19A1CYP3A4MEN1
SCHEMBL4218584 0.85 LMNA (0.57) LMNAMAPTCYP19A1CYP3A4MEN1
SCHEMBL4218580 0.85 LMNA (0.59) LMNAMAPTCYP19A1CYP3A4MEN1
SCHEMBL5672145 0.84 LMNA (0.52) LMNAMAPTCYP19A1CYP3A4NR3C1
SCHEMBL7877720 0.84 LMNA (0.52) LMNAMAPTCYP19A1CYP3A4NR3C1
SCHEMBL4441997 0.84 LMNA (0.55) LMNAMAPTCYP19A1CYP3A4MEN1
SCHEMBL3476075 0.83 LMNA (0.59) LMNAMAPTCYP19A1CYP3A4NR3C1
SCHEMBL4210068 0.83 LMNA (0.59) LMNAMAPTCYP19A1CYP3A4NR3C1
SCHEMBL4210066 0.83 LMNA (0.61) LMNAMAPTCYP19A1CYP3A4NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419971-B2 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application BODOR LABORATORIES, INC. 2008-09-02 US disclosed
EP-1658083-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS BODOR, Nicholas S. (US) 2006-05-24 EP disclosed
EP-1653974-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION BODOR, Nicholas S. (US) 2006-05-10 EP disclosed
US-20050020551-A1 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application BODOR LABORATORIES, INC. 2005-01-27 US disclosed
WO-2005000317-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION BODOR NICHOLAS S (US) 2005-01-06 WO disclosed
WO-2004112800-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS BODOR NICHOLAS S (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020551-A1 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application NR3C1, NR3C2, HSD17B7 LMNA 3415/4885MAPT 4613/4885CYP19A1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.